SG
INMB icon

StoneX Group’s INmune Bio INMB Stock Holding History

StoneX Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6K Buy
+21,513
New +$29.8K ﹤0.01% 1271

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group's INMB Position: Q2 2026 in Review

StoneX Group opened a new position in INmune Bio (INMB) in Q2 2026: 21,513 shares worth $30.6K. The stake represents ﹤0.01% of the portfolio and ranks #1271 among its holdings.

83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • StoneX Group held 21,513 shares of INmune Bio worth $30.6K as of Q2 2026.
  • INmune Bio was a new StoneX Group position in Q2 2026.
  • INmune Bio made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1271 holding.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.